A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
A phase 3 trial of Oxaliplatin and Capecitabine in biliary tract cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure is a phase 3 interventional study registered as NCT07606599 by Sichuan Baili Pharmaceutical Co., Ltd., with 398 participants planned, started 2026-07-07 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1, Oxaliplatin, Calcium levofolinate, Fluorouracil, Irinotecan Hydrochloride Liposome and Irinotecan Hydrochloride.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Shares Oxaliplatin, SystImmune / Sichuan Biokin, Capecitabine, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Shares SystImmune / Sichuan Biokin, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialEvaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialProgrammed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
Shares Oxaliplatin, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine and the tag pipeline.